Stock Events

Stock Events

Repligen 

€154.35
50
+€0.00+0%Friday 16:30

Statistics

Day High
152.25
Day Low
152.2
52W High
170.2
52W Low
150
Volume
-
Avg. Volume
-
Mkt Cap
9.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 27Expected
Q2 2026
Q3 2026
0.39
0.42
0.45
0.48
Expected EPS
0.4158554505
Actual EPS
0.476205

Financials

6.56%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
640.62MRevenue
42.03MNet Income

Analyst Ratings

$139.11Average Price Target
The highest estimate is ⁦170.73⁩.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGN.XETRA. It's not an investment recommendation.
Amazon
15
AMZN
Apple
14
AAPL
Microsoft
12
MSFT
Tesla
12
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Danaher
DHR
Mkt Cap163.25B
Danaher Corporation operates in the life sciences field, offering products and services similar to Repligen's bioprocessing technologies, making them direct competitors in the biotech and pharmaceutical manufacturing sector.
Thermo Fisher Scientific
TMO
Mkt Cap257.71B
Thermo Fisher Scientific provides a range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics, overlapping with Repligen's offerings in bioprocessing and biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap9.95B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing with Repligen in the supply of bioprocessing equipment and consumables.
Sartorius
SARTF
Mkt Cap14.69B
Sartorius AG competes with Repligen in the bioprocessing market, offering similar bioprocess solutions including filters and single-use systems for the biopharmaceutical industry.
Illumina
ILMN
Mkt Cap35.63B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which, while more focused on genomics, competes with Repligen in the broader biotech research and development space.
Casey`s General Stores
CASY
Mkt Cap25.14B
Catalent, Inc. offers delivery technologies and development solutions for drugs, biologics, and consumer health products, competing with Repligen in the biomanufacturing and bioprocessing sectors.
Avantor
AVTR
Mkt Cap10.88B
Avantor, Inc. provides products and services to the life sciences and advanced technology industries, competing with Repligen in the supply of materials and consumables for bioprocessing.
Repligen
RGEN
Mkt Cap11.23B
Regeneron Pharmaceuticals, while primarily a biotechnology company focused on developing and commercializing pharmaceuticals, competes with Repligen through its demand and innovation in bioprocessing technologies for drug development.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc., as a biopharmaceutical company, indirectly competes with Repligen by developing bioprocessing technologies in-house for their drug development, representing competition for market share in bioprocessing solutions.
GE HealthCare Technologies
GEHC
Mkt Cap34.62B
GE Healthcare provides medical technology and digital solutions, including bioprocessing technologies that compete with Repligen's offerings in the life sciences and biopharmaceutical manufacturing sectors.

About

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Show More
CEO
Olivier Loeillot
Employees
2000
Country
United States
ISIN
US7599161095
WKN
000870980

Listings

MI
IT
1RGEN.MI
F
DE
RGN.F
STU
DE
RGN.STU
MU
DE
RGN.MU

0 Comments

Share your thoughts

FAQs

What is Repligen stock price today?▼
The current price of RGN.XETRA is €154.35 EUR — it has increased by +0% in the past 24 hours. Watch Repligen stock price performance more closely on the chart.
What is Repligen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Repligen stocks are traded under the ticker RGN.XETRA.
What is Repligen market cap?▼
Today Repligen has the market capitalization of 9.8B
When is the next Repligen earnings date?▼
Repligen is going to release the next earnings report on February 24, 2027.
What were Repligen earnings last quarter?▼
RGN.XETRA earnings for the last quarter are 0.48 EUR per share, whereas the estimation was 0.42 EUR resulting in a +14.51% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Repligen revenue for the last year?▼
Repligen revenue for the last year amounts to 640.62M EUR.
What is Repligen net income for the last year?▼
RGN.XETRA net income for the last year is 42.03M EUR.
How many employees does Repligen have?▼
As of November 8, 2026, the company has 2,000 employees.
In which sector is Repligen located?▼
Repligen operates in the Health & Wellness sector.
When did Repligen complete a stock split?▼
Repligen has not had any recent stock splits.
Where is Repligen headquartered?▼
Repligen is headquartered in WALTHAM, United States.